Tempest Therapeutics (FRA:3OS0) Total Liabilities: €8.59 Mil (As of Mar. 2026)


FRA:3OS0 Tempest Therapeutics Inc FRA:3OS0
32 GF Score
Price €5.82
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Total Liabilities?

Tempest Therapeutics FRA:3OS0 32 Total Liabilities is €8.59 Mil as of Mar. 2026. GuruFocus rates FRA:3OS0 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Tempest Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was €8.59 Mil.

Tempest Therapeutics's quarterly Total Liabilities declined from Sep. 2025 (€9.19 Mil) to Dec. 2025 (€8.77 Mil) and declined from Dec. 2025 (€8.77 Mil) to Mar. 2026 (€8.59 Mil).

Tempest Therapeutics's annual Total Liabilities declined from Dec. 2023 (€22.77 Mil) to Dec. 2024 (€21.36 Mil) and declined from Dec. 2024 (€21.36 Mil) to Dec. 2025 (€8.77 Mil).

Tempest Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Tempest Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics Total Liabilities Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 32.85 26.41 22.77 21.36 8.77

Tempest Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.45 12.75 9.19 8.77 8.59
FRA:3OS0
32GF Score
Tempest Therapeutics Inc FRA:3OS0
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Tempest Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.83+(5.934+0.0010000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.77

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=14.459-5.694
=8.77

Tempest Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.864+(5.722+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.59

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=9.297-0.711
=8.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €8.59 Mil mean?
Tempest Therapeutics (FRA:3OS0) has a Total Liabilities of €8.59 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Tempest Therapeutics and its competitors.
Is Tempest Therapeutics' Total Liabilities too high?
Tempest Therapeutics' current Total Liabilities is €8.59 Mil. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Total Liabilities compare to HOWL and INTI?
Tempest Therapeutics' Total Liabilities of €8.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Tempest Therapeutics and its competitors. Tempest Therapeutics's current Total Liabilities is €8.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (FRA:3OS0) has a current Total Liabilities of €8.59 Mil. The current Total Liabilities is €8.59 Mil. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Tempest Therapeutics (FRA:3OS0), the current Total Liabilities is €8.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Other Exchanges TPST:USA
Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score

Get the complete analysis for FRA:3OS0

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.82
Price